Vaccine Market

Vaccine Market

Vaccine Market to Reach US$ 76.9 Bn by 2032, driven by newly emerging infectious pathogenic diseases has influenced the need for effective vaccines across the globe: Global Insight Services

New York, February 2023: According to a new research study by Global Insight Services (GIS), the global Vaccine Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 76.9 Billion by 2032.

A vaccine is a biological which is used to boost the person’s immune system and help to provide immunization against chronic diseases. The suspension consists of either weakened or killed forms of disease-causing microorganisms that enhance immunity without causing diseases. The vaccine provides active immunity against a specific harmful agent such as diseases caused by a certain pathogen, injection, bacteria, virus, or parasites. By stimulating the immune system to attack the agent and eliminating these agents and increasing the life of adults and elderly individuals. After stimulation by a vaccine, B lymphocytes remain sensitized and ready to respond to the agent whenever it enters the body next time.

Request Sample Pages of this Research Report:

Vaccine Market: Key Trends and Drivers

The expanding availability of preventive as well as therapeutic vaccines for range of diseases will boost the market expansion. Furthermore, newly emerging infectious pathogenic diseases has influenced the need for effective vaccines across the globe. This has driven the R&D activities undertaken by the operational players as well as dedicated research institutes. Advancement in vaccine development technologies to increase its efficacy and liability will offer innovative solutions to address existing disease burden. The adoption of novel development approaches including DNA/RNA vaccines, nanoparticle vaccines, and rational design will foster the vaccines market expansion.

Vaccine Market: Restraints & Challenges

Some of the market obstacles include a scarcity of experienced specialists and significant investment costs, as well as legal and ethical concerns about the market methods and outcomes in numerous nations.

Vaccine Market Report Findings

The adult segment is likely to hold a dominant Vaccine Market share and grow at a substantial CAGR during the forecast period.

Based on age group, the market is bifurcated into S Pediatric, and Adult. Adult vaccines segment is projected to proceed at xx% CAGR during the forecast timeframe. This is attributable to increased COVID-19 vaccination rate among adults. Moreover, the awareness and improving accessibility of various preventive vaccines that helps to reduce the risk of severe infections in adults will drive the segment revenue. Additionally, some countries have established the vaccination policies and regulations for adults while travelling to particular nations to avoid the risk of disease transmission, that has further influenced the vaccination rate in adults.

The Inactivated segment is anticipated to hold a majority of the Vaccine Market size throughout the study period.

Based on the technology, the market is bifurcated into Conjugate, Live, Inactivated, Recombinant, Toxoid. Vaccines market from inactivated segment exceeded USD xx billion in 2022. This is attributed to the ability of inactivated vaccines in destruction of pathogen replication. This offers effective protection against various dreadful pathogenic diseases such as hepatitis A, influenza, polio, and rabies. Moreover, these vaccines prevent the reversal activity of pathogens to more pathogenic phenotype and avoids the interference with other functional molecules during the combination therapies. This leads to preference for inactivated technology over the live vaccines. Furthermore, as it can stored without refrigeration for certain period as the pathogen is dead, it offers ease in transportation and storage that will continue to increase its demand.

The Hepatitis segment is anticipated to hold a majority of the Vaccine Market size throughout the study period.

Based on the application, the market is bifurcated into Cancer, Hepatitis, Pneumococcal Disease, Influenza, Rotavirus, COVID-19, and others. The higher recommendation of HPV vaccination for preteens, teens as well as younger adults as it can lead to different types of cancer will enhance the industry landscape. For instance, as per the Centers for Disease Control and Prevention, each year, nearly 14 million Americans, including teens are anticipated to be infected with HPV. The vaccination also prevents the risk of cervical cancer development in women. Thus, increasing vaccination rate across the developed and developing regions to reduce further risk of severe diseases associated with HPV will stimulate the market statistics.

The Europe region is estimated to exhibit the highest growth rate during the Vaccine Market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. Europe vaccines market accounted for xx% revenue share in 2022. This is attributable to the adoption of new technologies and expanding awareness about the preventive vaccines in the region. The government organizations are implementing some strategies to broaden accessibility for the emerging infectious disease treatments including the COVID-19. In addition, the industry players entered in collaboration with non-government organizations to provide COVID-19 vaccines considering significantly increasing disease incidence in the region.

Have a question for our analyst:

Competitive Landscape

The global Vaccine Market report includes players are AstraZeneca plc., CSL Limited, Emergent BioSolutions Inc., GlaxoSmithKline plc., Johnson & Johnson, Merck & Co., Novavax, Pfizer Inc, Sanofi S.A., and Serum Institute of India, among others.

Recent Developments in the Blood-Brain Barrier Market:

  • In February 2021, Ceva partnered with the French National Research Institute for Agriculture, Food, and Environment (INRAE) for R&D in the prevention of infectious diseases from animal origin and improvement of animal health.
  • In January 2021, Zoetis launched the Poulvac Procerta HVT-IBD vaccine for the protection of poultry against Infectious Bursal Disease (IBD). This added to the company line of recombinant vector vaccines.
  • UNICEF and Pfizer entered into a supply agreement for the COVID-19 vaccines distribution throughout 2021. This has helped the company to maintain broaden its distribution across the globe, thereby driving the business revenue.

Vaccine Market Report Coverage

  • The report offers a comprehensive quantitative as well as qualitative analysis of the current global Vaccine Market outlook and estimations from 2021 to 2031, which helps to recognize the prevalent opportunities.
  • A thorough analysis of market trends and restraints is provided.
  • Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
  • The forecasts in this report are made by examining the recent trends along with future Vaccine Market potential from 2021 to 2031 in terms of revenue.
  • Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Vaccine Market are also analyzed.
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global kidney stones management market.

Global Vaccine Market Segmentation

By Age Group

  • Pediatric
  • Adult

By Technology

  • Conjugated
  • Live
  • Inactivated
  • Recombinant
  • Toxoid
  • Others

By Application

  • Cancer
  • Hepatitis
  • Pneumococcal Disease
  • Influenza
  • COVID-19
  • Others

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Rest of World
    • Latin America
    • Middle East
    • Africa

Key Players

  • AstraZeneca plc.
  • CSL Limited
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline plc.
  • Johnson & Johnson
  • Merck & Co.
  • Novavax
  • Pfizer Inc
  • Sanofi S.A.
  • Serum Institute of India